Compounds > resiquimod
Page last updated: 2024-09-04

resiquimod and Triple Negative Breast Neoplasms

resiquimod has been researched along with Triple Negative Breast Neoplasms in 1 studies

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's1 (100.00)2.80

Authors

AuthorsStudies
Chen, Q; Su, X; Wang, J; Xie, X; Zeng, S; Zhang, L1

Other Studies

1 other study(ies) available for resiquimod and Triple Negative Breast Neoplasms

ArticleYear
Bioresorbable Depot for Sustained Release of Immunostimulatory Resiquimod in Suppressing Both Primary Triple-Negative Breast Tumors and Metastatic Occurrence.
    Bioconjugate chemistry, 2021, 05-19, Volume: 32, Issue:5

    Topics: Adjuvants, Immunologic; Cell Line, Tumor; Delayed-Action Preparations; Humans; Imidazoles; Neoplasm Metastasis; Precision Medicine; Triple Negative Breast Neoplasms

2021